Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for kids with deadly brain tumors

NCT ID NCT04049669

First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 13 times

Summary

This study tests whether adding the drug indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers (glioblastoma, medulloblastoma, ependymoma, or DIPG) live longer without their cancer growing. Indoximod works by blocking a natural immune-suppressing pathway, potentially helping the body's immune system fight the tumor more effectively. The trial enrolls up to 130 participants and measures how long the cancer is controlled and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Augusta University, Georgia Cancer Center

    Augusta, Georgia, 30912, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University, Children's Heathcare of Atlanta

    Druid Hills, Georgia, 30322, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.